Yayın:
Pharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calves

dc.contributor.authorCorum, Orhan
dc.contributor.authorYildiz, Ramazan
dc.contributor.authorIder, Merve
dc.contributor.authorAltan, Feray
dc.contributor.authorOk, Mahmut
dc.contributor.authorUney, Kamil
dc.date.accessioned2026-01-04T12:53:14Z
dc.date.issued2019-06-14
dc.description.abstractAbstractThe aim of this study was to evaluate the pharmacokinetics and bioavailability of cefquinome (CFQ) and ceftriaxone (CTX) following intravenous (IV) and intramuscular (IM) administrations in premature calves. Using a parallel design, 24 premature calves were randomly divided into the two antibiotic groups. Each of the six animals in the first group received CFQ (2 mg/kg) through IV or IM administration. The second group received CTX (20 mg/kg) via the same administration route. Plasma concentrations of the drugs were analyzed by high‐performance liquid chromatography and noncompartmental methods. Mean pharmacokinetic parameters of CFQ and CTX following IV administration were as follows: elimination half‐life (t1/2λz) 1.85 and 3.31 hr, area under the plasma concentration–time curve (AUC0–∞) 15.74 and 174 hr * μg/ml, volume of distribution at steady‐state 0.37 and 0.45 L/kg, and total body clearance 0.13 and 0.12 L hr−1 kg−1, respectively. Mean pharmacokinetic parameters of CFQ and CTX after IM injection were as follows: peak concentration 4.56 and 25.04 μg/ml, time to reach peak concentration 1 and 1.5 hr, t1/2λz 4.74 and 3.62 hr, and AUC0–∞ 22.75 and 147 hr * μg/ml, respectively. The bioavailability of CFQ and CTX after IM injection was 141% and 79%, respectively. IM administration of CFQ (2 mg/kg) and CTX (20 mg/kg) can be recommended at 12‐hr interval for treating infections caused by susceptible bacteria, with minimum inhibitory concentration values of ≤0.5 and ≤4 μg/ml, respectively, in premature calves. However, further research is indicated to assess the pharmacokinetic parameters following multiple doses of the drug in premature calves.
dc.description.urihttps://doi.org/10.1111/jvp.12789
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/31197850
dc.description.urihttps://dx.doi.org/10.1111/jvp.12789
dc.description.urihttps://avesis.deu.edu.tr/publication/details/b0e87b02-1605-4f84-8c1c-4a6b958cad7a/oai
dc.description.urihttps://avesis.deu.edu.tr/publication/details/a78c342c-4f4f-457d-b807-bb22ca0a41da/oai
dc.description.urihttps://hdl.handle.net/11468/17719
dc.description.urihttps://hdl.handle.net/20.500.12395/38078
dc.identifier.doi10.1111/jvp.12789
dc.identifier.eissn1365-2885
dc.identifier.endpage639
dc.identifier.issn0140-7783
dc.identifier.openairedoi_dedup___::c09952ed171ee365433101d0902fbf1b
dc.identifier.orcid0000-0003-3168-2510
dc.identifier.orcid0000-0002-9017-763x
dc.identifier.orcid0000-0002-8674-4873
dc.identifier.pubmed31197850
dc.identifier.scopus2-s2.0-85067614931
dc.identifier.startpage632
dc.identifier.urihttps://hdl.handle.net/20.500.12597/37356
dc.identifier.volume42
dc.identifier.wos000501034000008
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofJournal of Veterinary Pharmacology and Therapeutics
dc.rightsOPEN
dc.subjectBioavailability
dc.subjectBacteria
dc.subjectCeftriaxone
dc.subjectMicrobial Sensitivity Tests
dc.subjectpremature calves
dc.subjectCefquinome
dc.subjectAnti-Bacterial Agents
dc.subjectCephalosporins
dc.subjectceftriaxone
dc.subjectAnimals, Newborn
dc.subjectArea Under Curve
dc.subjectPremature Calves
dc.subjectAnimals
dc.subjectPremature Birth
dc.subjectPharmacokinetics
dc.subjectCattle
dc.subjectbioavailability
dc.subjectpharmacokinetics
dc.subjectcefquinome
dc.subjectHalf-Life
dc.subject.sdg3. Good health
dc.titlePharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calves
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Orhan Corum","name":"Orhan","surname":"Corum","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0003-3168-2510"},"provenance":null}},{"fullName":"Ramazan Yildiz","name":"Ramazan","surname":"Yildiz","rank":2,"pid":null},{"fullName":"Merve Ider","name":"Merve","surname":"Ider","rank":3,"pid":null},{"fullName":"Feray Altan","name":"Feray","surname":"Altan","rank":4,"pid":{"id":{"scheme":"orcid","value":"0000-0002-9017-763x"},"provenance":null}},{"fullName":"Mahmut Ok","name":"Mahmut","surname":"Ok","rank":5,"pid":null},{"fullName":"Kamil Uney","name":"Kamil","surname":"Uney","rank":6,"pid":{"id":{"scheme":"orcid","value":"0000-0002-8674-4873"},"provenance":null}}],"openAccessColor":null,"publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Bioavailability"},"provenance":null},{"subject":{"scheme":"keyword","value":"Bacteria"},"provenance":null},{"subject":{"scheme":"keyword","value":"Ceftriaxone"},"provenance":null},{"subject":{"scheme":"FOS","value":"0402 animal and dairy science"},"provenance":null},{"subject":{"scheme":"keyword","value":"Microbial Sensitivity Tests"},"provenance":null},{"subject":{"scheme":"FOS","value":"04 agricultural and veterinary sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"premature calves"},"provenance":null},{"subject":{"scheme":"keyword","value":"Cefquinome"},"provenance":null},{"subject":{"scheme":"keyword","value":"Anti-Bacterial Agents"},"provenance":null},{"subject":{"scheme":"keyword","value":"Cephalosporins"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null},{"subject":{"scheme":"keyword","value":"ceftriaxone"},"provenance":null},{"subject":{"scheme":"FOS","value":"0403 veterinary science"},"provenance":null},{"subject":{"scheme":"keyword","value":"Animals, Newborn"},"provenance":null},{"subject":{"scheme":"keyword","value":"Area Under Curve"},"provenance":null},{"subject":{"scheme":"keyword","value":"Premature Calves"},"provenance":null},{"subject":{"scheme":"keyword","value":"Animals"},"provenance":null},{"subject":{"scheme":"keyword","value":"Premature Birth"},"provenance":null},{"subject":{"scheme":"keyword","value":"Pharmacokinetics"},"provenance":null},{"subject":{"scheme":"keyword","value":"Cattle"},"provenance":null},{"subject":{"scheme":"keyword","value":"bioavailability"},"provenance":null},{"subject":{"scheme":"keyword","value":"pharmacokinetics"},"provenance":null},{"subject":{"scheme":"keyword","value":"cefquinome"},"provenance":null},{"subject":{"scheme":"keyword","value":"Half-Life"},"provenance":null}],"mainTitle":"Pharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calves","subTitle":null,"descriptions":["<jats:title>Abstract</jats:title><jats:p>The aim of this study was to evaluate the pharmacokinetics and bioavailability of cefquinome (CFQ) and ceftriaxone (CTX) following intravenous (IV) and intramuscular (IM) administrations in premature calves. Using a parallel design, 24 premature calves were randomly divided into the two antibiotic groups. Each of the six animals in the first group received CFQ (2 mg/kg) through IV or IM administration. The second group received CTX (20 mg/kg) via the same administration route. Plasma concentrations of the drugs were analyzed by high‐performance liquid chromatography and noncompartmental methods. Mean pharmacokinetic parameters of CFQ and CTX following IV administration were as follows: elimination half‐life (<jats:italic>t</jats:italic><jats:sub>1/2λz</jats:sub>) 1.85 and 3.31 hr, area under the plasma concentration–time curve (AUC<jats:sub>0–∞</jats:sub>) 15.74 and 174 hr * μg/ml, volume of distribution at steady‐state 0.37 and 0.45 L/kg, and total body clearance 0.13 and 0.12 L hr<jats:sup>−1</jats:sup> kg<jats:sup>−1</jats:sup>, respectively. Mean pharmacokinetic parameters of CFQ and CTX after IM injection were as follows: peak concentration 4.56 and 25.04 μg/ml, time to reach peak concentration 1 and 1.5 hr, <jats:italic>t</jats:italic><jats:sub>1/2λz</jats:sub> 4.74 and 3.62 hr, and AUC<jats:sub>0–∞</jats:sub> 22.75 and 147 hr * μg/ml, respectively. The bioavailability of CFQ and CTX after IM injection was 141% and 79%, respectively. IM administration of CFQ (2 mg/kg) and CTX (20 mg/kg) can be recommended at 12‐hr interval for treating infections caused by susceptible bacteria, with minimum inhibitory concentration values of ≤0.5 and ≤4 μg/ml, respectively, in premature calves. However, further research is indicated to assess the pharmacokinetic parameters following multiple doses of the drug in premature calves.</jats:p>"],"publicationDate":"2019-06-14","publisher":"Wiley","embargoEndDate":null,"sources":["Crossref"],"formats":["application/pdf"],"contributors":["Selcuk University Institutional Repository"],"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Journal of Veterinary Pharmacology and Therapeutics","issnPrinted":"0140-7783","issnOnline":"1365-2885","issnLinking":null,"ep":"639","iss":null,"sp":"632","vol":"42","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::c09952ed171ee365433101d0902fbf1b","originalIds":["10.1111/jvp.12789","50|doiboost____|c09952ed171ee365433101d0902fbf1b","31197850","2951851443","b0e87b02-1605-4f84-8c1c-4a6b958cad7a","50|od______2605::29af04356e852c3eb41260db4721b8a2","50|od______2605::751628a76d18c98aef47b73ddc57b08c","a78c342c-4f4f-457d-b807-bb22ca0a41da","oai:acikerisim.dicle.edu.tr:11468/17719","50|od______3346::7cd8f1b993601c57642b1f13882cf59d","oai:acikerisim.selcuk.edu.tr:20.500.12395/38078","50|od______4883::4bfc94bef6b417257ff320e325bc56d6"],"pids":[{"scheme":"doi","value":"10.1111/jvp.12789"},{"scheme":"pmid","value":"31197850"},{"scheme":"handle","value":"11468/17719"},{"scheme":"handle","value":"20.500.12395/38078"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":10,"influence":2.9014824e-9,"popularity":8.254217e-9,"impulse":4,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1111/jvp.12789"}],"license":"Wiley Online Library User Agreement","type":"Article","urls":["https://doi.org/10.1111/jvp.12789"],"publicationDate":"2019-06-14","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"31197850"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12789"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/31197850"],"publicationDate":"2020-04-28","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"mag_id","value":"2951851443"},{"scheme":"doi","value":"10.1111/jvp.12789"}],"type":"Article","urls":["https://dx.doi.org/10.1111/jvp.12789"],"refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12789"}],"type":"Article","urls":["https://avesis.deu.edu.tr/publication/details/b0e87b02-1605-4f84-8c1c-4a6b958cad7a/oai"],"publicationDate":"2019-11-01","refereed":"nonPeerReviewed"},{"type":"Conference object","urls":["https://avesis.deu.edu.tr/publication/details/a78c342c-4f4f-457d-b807-bb22ca0a41da/oai"],"publicationDate":"2017-05-17","refereed":"nonPeerReviewed"},{"pids":[{"scheme":"handle","value":"11468/17719"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12789"}],"type":"Article","urls":["https://hdl.handle.net/11468/17719","https://doi.org/10.1111/jvp.12789"],"publicationDate":"2024-04-24","refereed":"nonPeerReviewed"},{"pids":[{"scheme":"handle","value":"20.500.12395/38078"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12789"}],"type":"Article","urls":["https://doi.org/10.1111/jvp.12789","https://hdl.handle.net/20.500.12395/38078"],"publicationDate":"2019-01-01","refereed":"nonPeerReviewed"}],"isGreen":true,"isInDiamondJournal":false}
local.import.sourceOpenAire
local.indexed.atWOS
local.indexed.atScopus
local.indexed.atPubMed

Dosyalar

Koleksiyonlar